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Abstract: Objectives: To study the efficacy of rituximab in active rheumatoid arthritis (RA) patients refractory to disease 
modifying anti-rheumatic drugs (DMARDs) including the tumor necrosis factor (TNF)- antagonists. 
Methods: Adult patients with active RA despite adequate therapies with conventional DMARDs or anti-TNF agents for 
at least 3 months were recruited. Inclusion criteria were: (1) Positive RF / anti-CCP; (2)  6 swollen joints and  8 tender 
joints; (3) ESR  28 mm/hr or CRP  10 mg/L. Eligible patients were given intravenous rituximab infusions at a dose of 
1000 mg on days 1 and 15. Assessment was performed 4-weekly thereafter and included tender joint counts (TJC), swol-
len joint counts (SJC), physician’s and patient’s global assessment, patient’s pain assessment (VAS 0-100 mm), disability 
index (HAQ-DI), quality of life (SF36), fatigue score (FACIT-F), ESR and CRP. The DAS28, EULAR and ACR re-
sponses at week 24 were evaluated. 
Results: 10 patients (8 women and 2 men) were studied (mean age: 49 years; mean RA duration 7.4 years). Baseline TJC 
and SJC were 25.1 ± 13.2 and 12.8 ± 5.4 respectively. The mean DAS28 score was 7.1 ± 0.7, and the mean CRP and ESR 
levels were 52.3 ± 60 mg/L and 95.8 ± 32 mm/hr, respectively. The median number of failed DMARDs was 4 and two pa-
tients had failed anti-TNF treatment. At week 24, there was a significant drop in TJC, SJC, ESR and CRP. The HAQ-DI 
score also decreased from 2.1 to 1.7 (p=0.04) while the total SF-36 score improved from 24.8 to 38.3 (p=0.008). Sixty 
percent of patients achieved EULAR moderate-to-good response. Half of the patients achieved ACR20 and two achieved 
ACR50 / 70 response. Only one patient experienced a minor infusion reaction. 
Conclusions: Rituximab is effective and well tolerated in patients with refractory RA. 
Keywords: Biologics, rituximab, anti-TNF, refractory, treatment. 
INTRODUCTION 
  Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease that leads to significant disability and mortality. Conven-
tional disease modifying anti-rheumatic drugs (DMARDs) 
include methotrexate (MTX), leflunomide (LEF), sulphasa-
lazine (SSz), hydroxychloroquine (HCQ) and gold com-
pounds. Despite the use of these agents as monotherapy or 
combination therapy, a substantial proportion of patients still 
cannot achieve a clinically meaningful clinical response. For 
patients with inadequate response to conventional DMARD 
therapies, the anti-tumor necrosis factor (TNF)- agents such 
as infliximab, etanercept and adalimumab are treatment op-
tions. However, data from western countries have shown that 
around 50-60% of patients may achieve an American College 
of Rheumatology (ACR) 20 response [1-3]. Other patients are 
either withdrawn from the TNF inhibitors because of ineffi-
cacy or experiencing adverse effects. 
  Because of the lack of universal efficacy of the TNF 
inhibitors, a number of non-TNF biological agents have 
been developed. One of these, rituximab, is a chimeric 
monoclonal antibody directed against the CD20 antigen on 
the surface of B cells [4]. Administration of rituximab leads 
to selective depletion of the CD20 positive B cells from the  
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body, leaving the stem cells and plasma cells unaffected be-
cause CD20 is not expressed on these cells. 
  Rituximab was first reported to be useful in refractory 
RA [5]. A phase II randomized controlled trial has shown 
efficacy in RA patients refractory to MTX [6]. With the ad-
dition of rituximab, an ACR20 response could be achieved in 
73% of the patients as compared to 38% when MTX alone 
was continued. An extended follow-up of these patients at 48 
weeks showed that the ACR response was sustained in some 
patients, with significant improvement in physical function, 
as measured by the Health Assessment Questionnaire Dis-
ability Index (HAQ-DI) being evident at week 24 [7]. A fur-
ther extended follow-up of these patients at 1 and 2 years 
showed that a significantly higher proportion of patients who 
received rituximab plus MTX had improvement in HAQ-DI 
to a greater extent than the minimally clinically significant 
difference than those who received MTX alone [8]. 
  A more recent double-blind placebo-controlled clinical 
study (DANCER) confirmed that in RA patients who were 
refractory to conventional therapies and the TNF inhibitors, 
rituximab treatment (2 doses of 1000 mg or 500 mg) led to 
significantly higher rates of ACR responses and EULAR 
moderate / good responses when compared to placebo infu-
sion [9]. Rituximab was safe and well tolerated. The fre-
quency of infectious complications was similar between 
treatment and placebo groups. Reactions to the first infusion 
occurred in one-third of patients receiving 1000 mg rituxi-
mab infusion and could be minimized by intravenous corti-
costeroid pre-medication. 2    The Open Rheumatology Journal, 2007, Volume 1  Ho et al. 
  The experience of rituximab in RA is limited in Hong 
Kong. We conducted this open-label cohort study to evaluate 
the efficacy and tolerability of rituximab in our local Chinese 
patients with active RA who were refractory to DMARD and 
anti-TNF therapies. 
PATIENTS AND METHODS 
  Patients with active RA despite conventional DMARD or 
anti-TNF therapies were recruited. The inclusion criteria 
were: (1)  18 years of age; (2) 1987 ACR criteria for the 
classification of RA [10]; (3) Ability to give informed con-
sent and comply with the protocol and assessment; (4) Posi-
tive for either rheumatoid factor (RF) or anti-CCP antibody; 
(5) Active RA despite therapies with conventional DMARDs 
or the anti-TNF agents for at least 3 months, as evidenced by 
 6 swollen joints (66 joint count system) and  8 tender 
joints (68 joint count system); (6) Raised erythrocyte sedi-
mentation rate (ESR) to  28 mm/hr or C-reactive protein 
(CRP)  10 mg/L; (7) Stable dose of conventional DMARDs 
for at least 8 weeks prior to study entry or washout for at 
least 4 weeks (except for methotrexate and leflunomide, 
which were to be continued); (9) Use of anti-TNF agents 
(infliximab, etanercept or adalimumab) for at least 3 months 
and washout (etanercept for at least 2 weeks, infliximab or 
adalimumab for at least 8 weeks). 
  Exclusion criteria were: (1) Major surgery (including 
joint surgery) within 8 weeks prior to study entry; (2) Func-
tional class IV as defined by the ACR classification of func-
tional status in RA [11]; (3) Treatment with other investiga-
tional agents within 4 weeks of study entry (eg. anti-IL6, 
anti-CD4); (4) Treatment with gamma globulin, plas-
mapheresis or Prosorba column within six months of study 
entry; (5) Intra-articular steroid injection 6 weeks before 
study entry; (6) Immunization with a live/attenuated vaccine 
within 4 weeks prior to study entry; (7) History of severe 
allergic reaction to human, humanized or murine monoclonal 
antibodies; (8) Active current bacterial, viral, fungal, myco-
bacterial or other infections; (9) Chronic hepatitis B or hepa-
titis C carriers; (10) History of malignancies, including solid 
tumors and hematologic malignancies; (11) Pregnant women 
or lactating mothers. 
  This study was approved by the Research and Ethics 
committee of our hospital. Written consent was obtained from 
all participants. 
Protocol 
  Patients were given rituximab 1000 mg by intravenous 
infusion on Day 1 and Day 15. Routine pre-medication was 
not given. Intravenous hydrocortisone (100 mg) and chlor-
pheniramine (10 mg) were to be given if patients developed a 
reaction to the infusion. Methotrexate was to be continued 
throughout the study period, together with folic acid. Lefluno-
mide was also to be continued. The use of non-steroidal anti-
inflammatory drugs (NSAIDs) was allowed. Other DMARDs 
were stopped for at least 4 weeks prior to study entry. 
Clinical Assessments on Follow-Up Visits 
  Patients were followed up four-weekly for clinical re-
sponse and side effects to rituximab infusion. The following 
was assessed: tender joint count ([TJC]; 0-68), swollen joint 
count ([SJC]; 0-66), patient’s pain assessment, patient’s 
global assessment and physician’s global assessment as re-
corded by visual analog scale (VAS) 0-100 mm. Physical 
functioning and disability was assessed by Health Assess-
ment Questionnaire-Disability Index (HAQ-DI). Quality of 
life was assessed by the short form (SF)-36 questionnaire 
(Hong Kong Chinese version) [12]. Fatigue was assessed by 
the Functional Assessment of Chronic Illness Therapy-
Fatigue (FACIT-F) subscale [13]. The DAS28 scores were 
calculated at each clinic visit. 
Study End Points 
  The primary end-point of the trial was the proportion of 
patients who met the ACR20 and EULAR response criteria. 
Adverse Events 
  A checklist of possible adverse events related to rituxi-
mab was evaluated for participants at each clinic visit. 
Statistical Analyses 
  Unless otherwise stated, values expressed were mean ± 
standard deviation (SD). Continuous variables from baseline 
to various time intervals were compared by the non-
parametric Wilcoxon signed rank test. Statistical significance 
was defined as a p value of less than 0.05, two-tailed. Statis-
tical analyses were performed by the SPSS program (version 
11.5, Chicago IL, 2002). 
RESULTS 
  Twelve patients were screened but two of them were not 
eligible for study entry because of inadequate number of swol-
len and tender joints. Ten patients (two men and eight women) 
were finally recruited. All of them were ethnic Chinese. The 
median age was 49 years (range 42 to 62). The demographic 
and baseline disease characteristics are shown in Table 1. At 
study entry, all patients had very active RA as evidenced by a 
large number of TJC (25.1 ± 13.2) and SJC (12.8 ± 5.4), ele-
vated ESR (95.8 ± 32.3 mm/hr) and CRP (52.3 ± 53.5 mg/L) 
levels. Seven patients had radiological erosions at baseline. 
The median number of ineffective DMARDs in these patients 
was four. Two patients had failed anti-TNF treatment (in-
fliximab in one and both etanercept and infliximab in another 
patient). 
Table 1.  Clinical Characteristics of Patients at Study Entry 
 
Age, years (median, range) 
Women 
Duration of RA, years 
TJC, median (IQR) 
SJC, median (IQR) 
HAQ-DI, median (IQR) 
FACIT-F, median (IQR) 
DAS28, median (IQR) 
CRP, median (IQR) (mg/L) 
ESR, median (IQR) (mm/hr) 
Anti-CCP titer, median (IQR) 
No. of patients with baseline radiographic erosions 
Median number of failed DMARDs 















RA = rheumatoid arthritis; TJC = tender joint count; SJC = swollen joint count; HAQ = 
Health assessment questionnaire; FACIT-F = Functional Assessment of Chronic Illness 
Therapy-Fatique; DAS = disease activity score; CRP = C-reactive protein; ESR = 
erythrocyte sedimentation rate; CCP = citrullinated cyclic peptide; DMARD = disease 
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 Figs.  (1,2) show the number of patients who achieved the 
EULAR and ACR responses, respectively, at baseline and 
different time intervals. At week 24, 60% of the patients 
achieved EULAR moderate-to-good response. Half of the 
patients achieved ACR20, one achieved ACR50 and one 
achieved ACR70 response. The mean DAS28 scores de-
creased significantly from 7.1±0.7 at baseline to 5.6±1.2 at 
week 24 (p=0.005). Of the two patients who had failed anti-
TNF treatment, one showed moderate EULAR response 
while the other did not meet the criteria for a clinical re-
sponse despite a numerical improvement in the joint counts 
and DAS score. 
 
Fig. (1). EULAR responses at different time intervals following 
treatment with rituximab. 
 
 
Fig. (2). ACR20, ACR50 and ACR70 responses at different time 
intervals following treatment with rituximab. 
  Comparing the data at week 24 with baseline, there was a 
significant drop in the mean number of TJC (25.1 ± 13.2 to 
13.9 ± 14.7, p=0.005), and SJC (12.8 ± 5.4 to 5.7 ± 5.2, 
p=0.02). This was accompanied by a significant improve-
ment in the mean levels of ESR (95.8 ± 32.2 to 65.4 ± 41 
mm/hr, p=0.01) and CRP (52.3 ± 53.5 to 30.1 ± 42.6 mg/L, 
p=0.02). 
  The mean HAQ-DI score decreased from 2.1 ± 0.4 to 1.7 
± 2.6 (p=0.04). Seventy percent of patients had an improve-
ment from baseline of greater than 0.25 points of the HAQ-
DI, ie. the minimum clinically important difference (MCID) 
as described by Strand et al. [8]. Both the mental and physi-
cal health sub-scores of the SF-36 increased significantly 
from baseline to week 24. The mean fatigue (FACIT-F) 
score also improved significantly from 27.7 ± 7.4 to 20.1 ± 
6.6 (p=0.007). 
  Finally, the mean titers of RF dropped significantly from 
baseline to week 24 (42.0 ± 14 to 30.4 ± 12 IU/ml; p=0.005). 
The mean titers of anti-CCP also showed a trend of decrease 
(114 ± 103 to 105 ± 106 units; p=0.09). 
Adverse Events 
  Only one patient experienced transient urticaria during 
the first dose of rituximab infusion. It resolved after intrave-
nous hydrocortisone and chlorpheniramine. Drug infusion 
was completed without further problem. Premedication with 
hydrocortisone and chlorpheniramine was given to this pa-
tient before the second infusion. A mild skin reaction was 
noted during the infusion. This patient was known to have 
history of aspirin allergy and had had inadequate response to 
either infliximab and etanercept. No other adverse events 
were reported in other patients throughout the study. 
DISCUSSION 
  B cells may play an important role in the pathogenesis of 
RA. First, B cells may act as antigen presentation cells and 
activate T cells through the interaction between the MHC 
class II molecule and the T cell receptor. Second, B cells 
generate autoantibodies such as rheumatoid factor and anti-
citrullinated cyclic peptide (anti-CCP) antibodies. These 
antibodies may increase the inflammatory processes in the 
joints by promoting immune complex formation and com-
plement activation, and hence lead to joint erosion and dam-
age. 
  The efficacy of B cell depletion in rheumatoid arthritis 
confirms the role of B cells in the pathogenesis of RA [6, 9]. 
The proportion of patients who achieved ACR responses 
after rituximab treatment is very similar to that of the anti-
TNF agents [1-3]. In contrast to the TNF inhibitors, infec-
tive complications including tuberculosis and opportunistic 
infections are much less common with rituximab. 
  Our study showed that rituximab was efficacious for pa-
tients with active RA refractory to multiple DMARDs. De-
spite the lack of a placebo group, the improvement in our 
patients at the end of the study was unlikely to be spontane-
ous because they had active RA for at least 3 months prior to 
study entry. The ACR response rates achieved at week 24 
were quite similar to those reported in a placebo-controlled 
trial of rituximab in RA [9]. In addition to the improvement 
in joint swelling and tenderness, there was also a significant 
drop in the levels of serum inflammatory markers and RF 
titers, which was coupled with a significant improvement in 
quality of life and the disability index. 
  Despite the fact that we did not routinely prescribe intra-
venous or oral corticosteroids as pre-medication before ri-
tuximab infusion, none or our patients experienced serious 
infusion reactions. Only one patient developed mild infusion 
reaction which was settled with intravenous hydrocortisone 
injection. Rituximab infusion was not interrupted. No infec-
tion, mild or serious, was reported throughout the 24-week 
follow-up in our patients. Thus, the safety profile is quite simi-
lar to that in controlled trials [9, 14] in which no significant 
difference in the frequency of adverse events could be demon-
strated between rituximab and placebo groups of patients. 
  Apart from MTX and other conventional DMARDs, ri-
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respond to the anti-TNF agents. One of our patients who 
had failed infliximab achieved EULAR moderate response 
after one single course of rituximab. An open-label uncon-
trolled study of rituximab (100 mg on week 1, 375 mg/m2 on 
week 2, 500 mg/m2 on week 3 and 4) in 13 RA patients, 6 of 
whom were refractory to anti-TNF, showed that two third 
of patients achieved the ACR20 response at week 28 [15]. 
Another small uncontrolled series involving 10 patients 
showed that rituximab treatment (1000 mg for 2 doses 2 
week apart) resulted in moderate / good DAS28 response in 
80% of patients [16]. A more recent randomized controlled 
study called REFLEX trial (Randomized Evaluation of 
Long-Term Efficacy of Rituximab in RA) demonstrated that 
in patients who had inadequate response to one or more anti-
TNF agents, 2 infusions of 1000 mg of rituximab in addi-
tion to background MTX led to significantly higher response 
rates than MTX alone (EULAR moderate-to-good response 
65% vs 22%) [14]. 
  In summary, the current study showed that rituximab is 
effective in our local Chinese patients with persistently ac-
tive RA despite multiple DMARD therapies including the 
anti-TNF agents. Rituximab is a relatively safe option to be 
considered in these patients. 
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